Hims & Hers Halts Sale of Compounded Obesity Pill Amid Federal Scrutiny

Hims & Hers announced on Saturday that it will cease the sale of its compounded version of Novo Nordisk’s obesity medication. This decision follows a request from health officials for an investigation into potential violations of federal law by the telehealth company.

Earlier this week, Hims & Hers introduced the compounded drug, priced at $49 per month. The launch drew immediate criticism from Novo Nordisk, which had recently released the oral version of its injectable treatment, Wegovy, at a price range of $149 to $299 per month. The production of compounded medications is generally permitted only when a brand-name drug is in shortage, a situation that does not apply here.

The situation escalated when the Food and Drug Administration (FDA) announced its intent to take “decisive steps” against companies like Hims & Hers, which are marketing unapproved, compounded versions of GLP-1 medications. The FDA’s statement highlighted concerns over the safety and efficacy of such products.

On Friday, the Department of Health and Human Services formally requested the Department of Justice to investigate Hims & Hers for its actions. This inquiry reflects a growing concern regarding the practices of telehealth companies that operate outside of traditional pharmaceutical regulations.

The controversy centers on the broader implications for the telehealth industry and the regulation of compounded drugs. As telehealth services continue to expand, questions arise about the safety and legality of providing alternative medications that may not meet established standards.

In response to the backlash, Hims & Hers has stated that it remains committed to providing affordable healthcare solutions but will comply with regulatory guidance moving forward. The company is now reviewing its business practices in light of the investigation.

As this situation develops, both consumers and industry stakeholders will be watching closely to see how regulatory agencies respond to the challenges posed by the rapid growth of telehealth and compounded medications. The outcome may set important precedents for the future of drug marketing and patient access to treatments.